"On behalf of the Senti Bio team, I'd like to express our sincere gratitude to CIRM for its support of our Phase 1 trial of SENTI-202 and for recognizing SENTI-202's potential to improve the lives of people living with AML," said Timothy Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio. "We are proud of the clinical development progress to date as the Phase 1 trial continues to enroll and will remain steadfast in our mission to provide potentially lifesaving treatments for people living ...